Other Events ·
Alpha Tau Medical Ltd. reported positive clinical data for its Alpha DaRT therapy in combination with pembrolizumab…
DRTSAlpha Tau Medical Ltd.
Alpha Tau Medical Ltd. reported positive clinical data for its Alpha DaRT therapy in combination with pembrolizumab for treating head and neck squamous cell carcinoma. The study met its pre-specified success criterion, demonstrating a 100% objective response rate and a median overall survival of 18.2 months among evaluable patients. Alpha Tau Medical Ltd. is an Israeli oncology therapeutics company that develops Alpha DaRT technology for the treatment of solid tumors.